3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
May 29 - June 2, 2026 | Chicago, IL
▶️ At the Forefront of Oncology Progress
Veristat is pleased to attend the ASCO Annual Meeting, where oncology leaders, researchers, and clinicians gather to share the latest advances shaping cancer care. As new therapies move through development, the bar for clinical evidence continues to rise, and the path to approval demands both scientific depth and regulatory precision.
We’re looking forward to connecting with sponsors and oncology innovators to exchange perspectives on how programs are evolving in this environment. Veristat supports these efforts with integrated expertise across regulatory, clinical development, and biostatistics, helping teams translate complex data into decisions that hold up under scrutiny and keep development capital working efficiently.
👥 Meet with us at Booth 34098
Connect with us at the event to explore how Veristat’s scientific leadership and focused capabilities can help advance your clinical and regulatory milestones.
📅 Schedule a meeting in advance
Complete the form on this page to reserve time with our team. We welcome the opportunity to learn about your upcoming programs and explore how Veristat can support your development strategy.
💡 Our Expertise
Whether you're launching a first-in-human study or navigating complex regulatory pathways, Veristat delivers integrated expertise and personalized support across the development lifecycle:
-
Full-Service Clinical Development Solutions
-
Clinical Operations Excellence
-
Global Regulatory Strategy & Submissions
If you’ll be at the meeting, let’s make time to discuss how we can help move your programs forward.
Schedule A Meeting
Meet with us at the ASCO Annual Meeting
Chicago, IL | May 29- June 2, 2026
3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...